GlobeNewswire

Cisco ACI Is Data Center Solution of Choice for Service Providers Worldwide

Dela

Service providers deliver new cloud services more quickly and offer superior customer experience with the help of Cisco Application Centric Infrastructure

SAN JOSE, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- Providing secure, differentiated and rapidly delivered cloud services to customers is a crucial requirement for today's service providers.  To meet cloud infrastructure demands, global service providers are increasingly turning to the Cisco® Application Centric Infrastructure (Cisco ACI(TM)) the industry-leading software-defined networking (SDN) solution. Cisco ACI reduces operational costs with an automated, policy-based programmable architecture, while improving scalability and security. In addition, new Cisco ACI multi-site management capability helps service providers to connect and manage multiple geographically distributed Cisco ACI fabrics and to move and manage workloads with a single pane of glass.

Cisco ACI is being deployed worldwide by service providers such as NTT Communications (United States), T-Systems (Germany), Hosters (Denmark), scanplus GmbH (Germany), Tieto Oyj (Finland), and Ritter (United States).

NTT Communications
NTT Communications (NTT Com) is a subsidiary of NTT Group and a 20-year IT service provider veteran.   The U.S. division of NTT Com recognized a market opportunity to better serve the enterprise market with a portfolio of managed service offerings tailored to key vertical markets that would also meet compliance mandates and regulations. 

To succeed in this new direction, NTT Com decided to transform its data centers with a focus on greater security and performance. NTT Com selected Cisco ACI because it offered a much more agile management model over competing industry solutions.  NTT Com can now quickly set up highly complex data center domains, bringing new customers onboard in as little as three days, and the security policies inherent in Cisco's SDN solution also support the compliance needs of its customers. 

"Cisco ACI means applications guide the way the network acts, not the other way around," says Indranil Sengupta, vice president of product engineering at NTT Com.  "We're able to offer an outstanding customer experience with fewer errors and up to 80 percent better application performance."

T-Systems

With operations in more than 20 countries and multi-billion euro revenues, T-Systems, based in Germany, is one of the world's leading providers of information and communications technology.  Increasingly T-Systems midsize customers are requesting new services based on cloud services and innovative business models, such as data analytics, the Internet of Things, machine-to-machine communications, and industrial Internet.  T-Systems selected Cisco ACI to provide its customers with tailored infrastructure, platforms, and software solutions.

"Our customers want high quality services, uncompromised security, and flexibility, all at a reasonable price," says Andreas Schwall, Delivery Executive Production Midmarket at T-Systems. "Our challenge was to reduce IT effort and maintenance-based outages, while improving capacity at the network and security layer."

In addition, Cisco ACI allows T-Systems to run more agile, flexible operations and open up new security offerings for customers. "Based on open APIs and an application-centric view of our landscape, we can reduce lead times during the onboarding process and rapidly add more services to our portfolio," adds Schwall.

Now application traffic steers the network, rather than the other way around, enabling T-Systems to build the network environment around different customer applications, significantly improving performance and better meeting requirements.   Optimizing software-defined automation has reduced manual tasks by 90%, providing a productivity gain equivalent to three full-time employees.

Hosters
Hosters, located in Denmark, is a certified Microsoft Azure Managed Service Provider offering cloud and hybrid solutions.  The company turned to Cisco ACI to reduce time to market and to provide customers with the right solution easily and quickly.  Security was also an important consideration, and Hosters worked with Fortinet and Cisco ACI to ensure the highest levels of security for customers.  Cisco ACI is now operating in three Hosters data centers and baby spines, and the company is planning to upgrade its data centers to 100GbE, made easier with the Cisco ACI deployment.

"The results of the Cisco ACI deployment have exceeded our expectations," said Thomas Raabo, CTO, Hosters.  "Our deployment time of new services to customers has been cut down from weeks to hours, and we are spending less time on systems integration and more time on innovation.  We're moving to a DevOps model of continuous improvement, and we're creating agility and value that can be passed along to our customers."

scanplus GmbH
As a leading provider of managed cloud services in Germany, scanplus delivers to Deutsche Telekom business customers carrier-grade cloud services with rock-solid service level agreements throughout Europe. scanplus wanted to provide Deutsche Telekom customers with a "cloud in a box" that offered options and full automation and delivery through a self-service portal. scanplus chose Cisco ACI to address these needs, and will also benefit from a network fabric that scales to multiple sites, with single pane-of-glass management and automation.  Because scanplus is supporting a large number of business customers in a shared cloud environment, data protection and strict tenant segmentation are essential.   Designed for secure multi-tenancy, Cisco ACI makes it possible for applications and users to share the same infrastructure without leaking information across tenant boundaries. 

"With Cisco ACI, we have full segmentation of each tenant, and can also reference other tenant objects within a tenant while maintaining isolation, which makes them private, separated, and highly secure," said Stefan Daiber, head of architecture at scanplus.  

Using Cisco ACI multi-site functionality, scanplus is also in the process of extending its network fabric to multiple data centers.  Because the solution works with any vendor's hypervisor, it can easily accommodate the different systems in each location.

"The openness of Cisco ACI is a big benefit," said Daiber.  "It doesn't just support any hypervisor, but also all of the network equipment surrounding the hypervisor.  It gives us a tremendous amount of choice and flexibility."

Tieto Oyj
Tieto Oyj, headquartered in Finland, is a Nordic software and services company.   Tieto has deployed Cisco ACI as a Layer 2 fabric in six data centers in three countries.  Tieto's growth strategy is to shift from providing basic services to also delivering an outstanding experience for its customers. That means being able to deliver services quickly and making it possible to build anything on the application level that a customer wants-without being hindered by the underlying physical infrastructure.  

Tieto selected Cisco ACI solution to ensure a holistic architecture with centralized automation and policy-driven application profiles. Using the Cisco ACI unified policy model, the team enforces policy through endpoint groups (EPGs), a collection of network endpoints that includes a wide range of entities, including bare-metal servers, virtual machines, and containers.

"Cisco ACI provides a foundation that we can build on to channel innovation into new services," said Juha Syrjänen, Head of Connectivity Services Business at Tieto. "We'll be able to quickly and efficiently deliver basic connectivity services, while building a new connectivity ecosystem between our customers, their other partners, and Tieto."

Ritter Communications
Headquartered in the United States, Ritter Communications serves more than 45,000 customers in rural Arkansas and Tennessee with advanced voice and data services typically only found in major metropolitan areas.  Although Ritter Communications has provided local phone service since 1906, sheer connectivity doesn't deliver the revenues it once did.  Ritter needed to deliver a new set of business-focused cloud services to drive revenue growth.  But Ritter had limited operational experience with cloud services, and so did its customers.

"We serve a very rural market, and many network managers are tied to their servers.  They wouldn't feel comfortable putting everything in the public cloud," said Greg Sunderwood, vice president of engineering at Ritter Communications.   "We wanted more differentiation on the front end and more control on the back end."

Ritter's Hosted Solutions team found the answer in Cisco Cloud Architecture for the Microsoft Cloud Platform.  The integrated solutions feature a combination of Cisco ACI, Windows Azure Pack, and Cisco Unified Computing Systems (UCS®). 

"We essentially pull the public cloud into a customer's environment," says Brandon Fergerson, senior cloud engineer at Ritter Communications.  "Microsoft Azure is the customer-facing management console, and Cisco ACI handles back end infrastructure and network management."

The Hosted Solutions team has gone from manual provisioning to 100 percent virtual deployments, and customer spending for the new services is 50 to 60 percent higher than Ritter anticipated.

"We've turned server-hugging skepticism into cloud-first approaches," Fergerson says.  "I see it all the time.  The subscriptions start with just one low-risk server, then it seems like every time I check back on that tenant, they are adding more and more resources in the cloud as the trust grows.  The Ritter cloud is a simple, customer-friendly, highly automated offering, and it's been the catalyst for a mind shift-for us and our customers."

Additional Resources
Read case study: NTT CommunicationsRead case study:  T-SystemsRead case study:  scanplus GmbHRead case study: HostersRead case study:  Tieto OyjRead case study:  Ritter CommunicationsLearn more about: Cisco ACILearn more about Cisco ACI ecosystem partnersLearn more about: Cisco data center technology

About Cisco
Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at thenetwork.cisco.com and follow us on Twitter at @Cisco.

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.

RSS Feed for Cisco: http://newsroom.cisco.com/rss-feeds

Press Relations:          
Lee Davis                   
Cisco                          
650-868-3036             
leedavis@cisco.com   

Analyst Relations:      
Aimee Schoaf            
Cisco                          
623-377-0377             
aschoaf@cisco.com

Investor Relations
Carol Villazon
Cisco
408-527-6538
carolv@cisco.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum